Your session is about to expire
Anoro Ellipta vs Stiolto Respimat
Introduction
For patients with chronic obstructive pulmonary disease (COPD), certain drugs that relax the muscles around the airways and reduce inflammation can significantly improve breathing and manage symptoms. Anoro Ellipta and Stiolto Respimat are two such medications commonly prescribed for COPD. They each work differently but both effectively open up the airways, making it easier to breathe in people with COPD. Anoro Ellipta combines an anticholinergic agent called umeclidinium with a long-acting beta2-adrenergic agonist (LABA) named vilanterol, which primarily works by relaxing the muscles in your lungs to make breathing easier. On the other hand, Stiolto Respimat is a combination of tiotropium bromide (an anticholinergic) and olodaterol (a LABA). The dual-action effect of these agents serve to widen air passages allowing better oxygen flow.
Anoro Ellipta vs Stiolto Respimat Side By Side
| Attribute | Anoro ellipta | Stiolto respimat |
|---|---|---|
| Brand Name | Anoro Ellipta | Stiolto Respimat |
| Contraindications | Should not be used with certain types of medication including beta-blockers, not recommended for individuals whose COPD is significantly complicated by asthmatic conditions, not to be used as rescue therapy for acute bronchospasm. | Should not be used with certain types of medication including beta-blockers, not intended to be used as a rescue medicine for treating sudden breathing problems, not recommended for individuals whose COPD is significantly complicated by asthmatic conditions. |
| Cost | $400 for a one month supply | $350 for a one month supply |
| Generic Name | Umeclidinium/Vilanterol | Tiotropium/Olodaterol |
| Most Serious Side Effect | Signs of allergic reaction, symptoms related to heart problems, vision changes, problems with urination, high blood sugar, low potassium levels, new onset of wheezing symptoms. | Signs of an allergic reaction, rapid heartbeat, blurry vision or new visual disturbances, difficulty urinating, new onset seizures, unusual changes in mood or behavior. |
| Severe Drug Interactions | Beta-blockers due to the risk of interactions. | Beta-blockers due to the risk of interactions. |
| Typical Dose | One inhalation once daily | 2 inhalations once daily |
What is Anoro Ellipta?
Anoro Ellipta and Stiolto Respimat are both long-acting inhalers used to manage chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. They represent a major advancement in COPD treatment since the first generation of bronchodilators.
Anoro Ellipta, approved by the FDA in 2013, combines two drugs: Umeclidinium (an anticholinergic) and Vilanterol (a long-acting beta2-adrenergic agonist). It works by relaxing muscles around the airways in your lungs, helping you breathe more easily.
Stiolto Respimat includes Tiotropium bromide(an anticholinergic) and Olodaterol(a long-acting beta2-adrenergic agonist), offering similar benefits but with different active ingredients. Both medications are designed for once-daily use.
While Anoro has a selective influence on lung musculature with minor systemic effects due to Vilanterol's specificity for beta2 receptors, this results in fewer side effects compared to other bronchodilators that have stronger systemic effects.
What conditions is Anoro Ellipta approved to treat?
Anoro Ellipta is approved for the long-term maintenance treatment of airflow obstruction in patients with:
- Chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema
- It's also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
Stiolto Respimat, on the other hand, is used as a long-term once-daily maintenance treatment for airflow obstruction in patients with:
- Chronic obstructive pulmonary disease (COPD)
- Emphysema
- Chronic bronchitis
How does Anoro Ellipta help with these illnesses?
Anoro Ellipta helps to manage chronic obstructive pulmonary disease (COPD) by increasing the amount of airflow to the lungs. It achieves this through its two active ingredients: a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine, a chemical responsible for causing airway constriction, and a long-acting beta2-adrenergic agonist (LABA) that stimulates beta2-receptors in the lungs resulting in bronchodilation or widening of the airways. This dual action allows patients with COPD to breathe easier for longer periods of time.
Acetylcholine and Beta2 are substances found throughout our body involved in lung function, heart rate regulation, muscle contraction among other things. In individuals suffering from COPD, these chemicals can cause an imbalance leading to narrowing of air passages making it difficult for them to breathe. Therefore, by blocking acetylcholine and stimulating Beta2-receptors using Anoro Ellipta can limit negative effects associated with COPD helping patients manage their condition effectively.
What is Stiolto Respimat?
Stiolto Respimat is a brand name for the combination of tiotropium and olodaterol, both bronchodilators that help to relax muscles in the airways and increase airflow to the lungs. This medication acts as an anticholinergic and long-acting beta2-adrenergic agonist (LABA), which means it prevents constriction of smooth muscle in the respiratory tract and increases dilation by stimulating beta2 receptors within lung cells. Approved by the FDA in 2015, Stiolto Respimat is primarily used for treating chronic obstructive pulmonary disease (COPD). Unlike Anoro Ellipta, Stiolto Respimat does not contain a corticosteroid component which can have side effects such as oral thrush or hoarseness. However, like all medications, it may also cause some adverse reactions including upper respiratory infection, coughing, dry mouth or rapid heart rate but its benefit in keeping your COPD under control usually outweighs these potential risks. It's important to note that individuals who fail to respond adequately to "typical" bronchodilator therapy might find relief with this type of medication.
What conditions is Stiolto Respimat approved to treat?
Stiolto Respimat has been approved by the FDA for the long-term maintenance treatment of:
- Chronic obstructive pulmonary disease (COPD)
- Emphysema and chronic bronchitis
It is important to note that Stiolto Respimat is not intended to be used as a rescue medicine for treating sudden breathing problems.
How does Stiolto Respimat help with these illnesses?
Stiolto Respimat is a combination medication used to control and prevent symptoms such as shortness of breath, wheezing caused by chronic obstructive pulmonary disease (COPD). It contains two medications: Tiotropium and Olodaterol. Tiotropium works like an anticholinergic, blocking the action of acetylcholine in the airways thereby relaxing them. This makes breathing easier for patients with COPD. On the other hand, Olodaterol is a long-acting beta2-adrenergic agonist which opens up the airways by relaxing surrounding muscles.
This dual-action approach tends to make Stiolto Respimat more effective than single-mechanism drugs at managing COPD symptoms. Comparatively, Anoro Ellipta also combines two active ingredients but its mechanism may not work well for everyone especially those who have certain types of allergies or heart conditions. Therefore, Stiolto Respimat might be prescribed when a patient does not respond adequately to other bronchodilators or has specific contraindications.
How effective are both Anoro Ellipta and Stiolto Respimat?
Anoro Ellipta and Stiolto Respimat are both reliable treatment options for Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema. They were approved by the FDA just a year apart, with Anoro being first to market in 2013. Each medication works through different mechanisms of action: Anoro contains a long-acting muscarinic antagonist (LAMA) named Umeclidinium along with a long-acting beta2-adrenergic agonist (LABA) called Vilanterol while Stiolto Respimat combines Tiotropium Bromide as its LAMA component and Olodaterol as its LABA.
In terms of efficacy, studies have shown comparable results between these two medications in improving lung function, reducing exacerbations and enhancing quality of life among COPD patients. In fact, no significant differences were noted across most metrics used to evaluate their effectiveness.
Adverse effect profiles for both drugs are similar too although subtle distinctions do exist; dry mouth has been more frequently reported with Anoro while nasopharyngitis is more commonly associated with Stiolto usage.
The optimal dosage for each differs slightly - one inhalation per day from the pre-filled device in case of Anoro whereas two inhalations once daily is recommended when using Stiolto Respimat.
It's worth noting that some recent meta-analyses found both drugs seem superior compared to monotherapy or placebo for treating COPD symptoms thus solidifying their positions as potent treatment choices particularly after initial treatments fail to deliver satisfactory responses or if there's need to avoid certain side effects common with other drug classes used against COPD like corticosteroids which can induce weight gain.
Related trials for anoro ellipta and stiolto respimat
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Anoro Ellipta typically prescribed?
Inhaled dosages of Anoro Ellipta comprise one inhalation once daily, and studies suggest this is effective for managing chronic obstructive pulmonary disease (COPD) in most adults. This medication is not recommended for use in children or adolescents due to lack of safety and efficacy data. Similarly, Stiolto Respimat's prescribed dosage is also two puffs taken orally once a day. In both cases, the dose should not be increased beyond the advised limit since overdosage can lead to adverse effects. It's important to note that neither Anoro Ellipta nor Stiolto Respimat should be used as rescue therapy for sudden breathing problems.
At what dose is Stiolto Respimat typically prescribed?
Stiolto Respimat treatment is typically initiated at the dose of 2 inhalations once daily. The medication comes in a pre-filled inhaler device that delivers 60 doses, enough for one month. Each Stiolto Respimat spray contains two active ingredients: Tiotropium Bromide and Olodaterol, which work together to relax your airway muscles for up to 24 hours. This makes breathing easier by improving lung function throughout the day and night. It is important not to exceed the recommended dosage as it will not provide additional benefits and may increase side effects risk. If there's no improvement in symptoms after several weeks on this regimen, consultation with a healthcare provider is necessary.
What are the most common side effects for Anoro Ellipta?
Common side effects of Anoro Ellipta may include:
- Upper respiratory tract infection
- Pneumonia
- Bronchitis
- Cough
- Thrush in your mouth and throat (yeast infection)
- Hoarseness or voice changes
- Headache
- Rapid heart rate or palpitations
On the other hand, Stiolto Respimat can cause side effects such as:
- Nasopharyngitis (the common cold)
- Back pain
- Cough
-Diarrhea
-Dizziness
-Rash
-Bronchitis
-Arthritis
Remember, it's important to notify your healthcare provider if you experience any adverse reactions while taking these medications.
Are there any potential serious side effects for Anoro Ellipta?
Anoro Ellipta and Stiolto Respimat are both medicines used to treat chronic obstructive pulmonary disease (COPD). While they may cause similar side effects, there are some differences that you should be aware of:
- Signs of allergic reaction: hives, difficulty breathing or swallowing, swelling in your face, lips, tongue or throat
- Symptoms related to heart problems such as chest pain, rapid heartbeats or fluttering in your chest. This may also include sudden dizziness and feeling like you might pass out.
- Vision changes like seeing halos around lights or blurred vision. Eye pain or redness can also occur.
- Problems with urination - little or no urinating; painful or difficult urination; dark coloured urine; blood in the urine
- High blood sugar - increased thirst, increased frequency of urination especially at night time; dry mouth and fruity breath odor
- Low potassium levels could lead to leg cramps, constipation irregular heartbeats
- New onset of wheezing symptoms after using these medications.
If any severe symptoms appear during treatment with either Anoro Ellipta or Stiolto Respimat it is important to seek immediate medical attention. Remember everyone's body reacts differently so what applies for one person does not necessarily apply for all.
What are the most common side effects for Stiolto Respimat?
Stiolto Respimat, a medication used for treating chronic obstructive pulmonary disease (COPD), might lead to the following side effects:
- Dry mouth or throat discomfort
- Nasal congestion
- Headache, dizziness
- Coughing and hoarseness
- Rapid heartbeat or palpitations
- Nervousness or anxiety
- Difficulty with sleep (insomnia)
- Blurred vision
- Rash and itching
- Increased frequency of urination -Unexplained weight loss -Muscular pains and cramping.
Remember that while some patients may experience these side effects, others may not have any adverse reactions at all. Always consult your healthcare provider before starting any new medication regimen.
Are there any potential serious side effects for Stiolto Respimat?
While Stiolto Respimat is generally safe and well tolerated, certain serious side effects may occur in some patients. These can include:
- Signs of an allergic reaction such as rash, itching or hives on the skin; swelling of the face, lips, tongue or other parts of the body; shortness of breath, wheezing or difficulty breathing
- Rapid heartbeat (tachycardia)
- Blurry vision or new visual disturbances
- Difficulty urinating
- New onset seizures
- Unusual changes in mood or behavior such as confusion
- New troubles with sleep
Should you experience any of these symptoms while using Stiolto Respimat it's imperative to contact your healthcare provider immediately.
Contraindications for Anoro Ellipta and Stiolto Respimat?
Anoro Ellipta and Stiolto Respimat, like most chronic obstructive pulmonary disease (COPD) medications, may worsen symptoms in some patients. If you notice your breathing becoming more difficult or labored, please seek immediate medical attention.
Neither Anoro Ellipta nor Stiolto Respimat should be used if you are taking certain types of medication including beta-blockers due to the risk of interactions. Always inform your physician about any other drugs or supplements that you're taking; such substances might require a clearance period to prevent dangerous interactions with Anoro Ellipta and Stiolto Respimat.
Furthermore, these medications should not be used as rescue therapy for acute bronchospasm (sudden worsening of shortness of breath). Also note that they can increase the risk of asthma-related death. Therefore, they aren't recommended for individuals whose COPD is significantly complicated by asthmatic conditions.
It's also crucial to mention any pre-existing heart conditions before starting treatment since both drugs could potentially exacerbate cardiovascular complications.
How much do Anoro Ellipta and Stiolto Respimat cost?
For the brand names of these inhalers:
- The price for a one month supply of Anoro Ellipta (umeclidinium/vilanterol) averages around $400, with each dose costing approximately $13/day.
- A monthly supply of Stiolto Respimat (tiotropium/olodaterol) is generally less expensive, averaging around $350 and working out to roughly $11.70/day.
Thus, if you are considering cost as part of your decision-making process, Stiolto Respimat might be more affordable on a per-day treatment basis. However, remember that cost should not be the primary consideration when determining which medication is best suited for your needs.
Currently, there are no generic versions available for either Anoro Ellipta or Stiolto Respimat. Therefore, costs remain relatively high compared to some medications where generics are available. Insurance coverage may significantly impact final out-of-pocket expenses.
Popularity of Anoro Ellipta and Stiolto Respimat
Anoro Ellipta and Stiolto Respimat are both prescription medicines used for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Anoro Ellipta was prescribed to about 1.3 million people in the USA in 2020, accounting for almost 11% of total COPD prescriptions. It's popularity has been increasing since its introduction due to its ease-of-use as an inhaler that delivers a once-daily dose.
Stiolto Respimat, on the other hand, was prescribed to approximately 900 thousand individuals within the same timeframe. In terms of overall COPD treatments, it makes up around 8%. This drug also provides daily doses using an easy-to-use inhaler system but requires two puffs compared to Anoro’s one puff per day regimen which might be a factor affecting patient preference.
Both these drugs have shown steady growth over recent years in their usage rates as they provide key benefits such as convenience and effective symptom management for those suffering from COPD.
Conclusion
Both Anoro Ellipta and Stiolto Respimat have long-standing records of usage in patients with Chronic Obstructive Pulmonary Disease (COPD), and are backed by numerous clinical studies indicating that they provide better lung function compared to placebo treatments. They both contain two different types of bronchodilators: a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic agonist (LABA). These help the muscles around the airways in your lungs stay relaxed to prevent symptoms such as wheezing, coughing, chest tightness, and shortness of breath.
Due to their similar mechanisms of action, it might seem difficult at first glance to differentiate when one would be prescribed over the other. However, there may be individual patient factors that could influence this decision like cost or ease-of-use considerations.
Anoro Ellipta comes in an inhaler device that provides 30 doses whereas Stiolto Respimat is supplied as a cartridge providing 60 doses which needs to be inserted into a reusable inhaler device. The choice between these medications could simply come down to preference for how each device feels or operates.
While both drugs are generally well-tolerated, side effects may occur including dry mouth, sore throat or upper respiratory tract infection. It's also important for patients starting on either treatment option monitor any changes in symptoms closely - if you notice any worsening breathing problems while taking these medications seek immediate medical attention.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Scott, L. J., & Hair, P. (2014, February 15). Umeclidinium/Vilanterol: First Global Approval. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-014-0186-8
- Blair, H. A., & Deeks, E. D. (2014, November 15). Umeclidinium/Vilanterol: A Review of Its Use as Maintenance Therapy in Adults with Chronic Obstructive Pulmonary Disease. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-014-0326-1
- Miravitlles, M., Baek, S., Vithlani, V., & Lad, R. (2018). Optimal Bronchodilation for COPD Patients: Are All Long-Acting β<sub>2</sub>-Agonist/Long-Acting Muscarinic Antagonists the Same?. Tuberculosis and Respiratory Diseases. The Korean Academy of Tuberculosis and Respiratory Diseases.http://doi.org/10.4046/trd.2018.0040
- Dhillon, S. (2015, December 18). Tiotropium/Olodaterol: A Review in COPD. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-015-0527-2
- Blair, H. A. (2019, May 22). Tiotropium/Olodaterol: A Review in COPD. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-019-01133-w
- Ramadan, W. H., Al Masri, S., & Rizk, J. (2019, September 2). Fixed‐dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review. The Clinical Respiratory Journal. Wiley.http://doi.org/10.1111/crj.13073
- Gras, J. (2014). Umeclidinium/vilanterol fixed-dose combination for COPD. Drugs of Today. Portico.http://doi.org/10.1358/dot.2014.50.3.2122119
- Beeh, K. M., Derom, E., Echave-Sustaeta, J., Grönke, L., Hamilton, A., Zhai, D., & Bjermer, L. (2016, February). The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and luticasone propionate via Accuhaler® (ENERGITO® study). International Journal of Chronic Obstructive Pulmonary Disease. Informa UK Limited.http://doi.org/10.2147/copd.s95055